课题基金 / 基金详情

Short Chain Fatty Acids and Streptococcus Pyogenes Virulence

Short Chain Fatty Acids and Streptococcus Pyogenes Virulence
短链脂肪酸和化脓性链球菌毒力
批准号:
9982473
负责人:
Michael G. Caparon
金额:
$35.33万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-07-01 至 2021-07-31

项目摘要

项目成果

Michael G. Caparon的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 微生物来源的短链脂肪酸(SCFAs)已成为“疾病”的重要介质 耐受性”是一个试图限制免疫耐受对宿主组织的附带损害的过程, 应答最好的理解是在肠道中,由肠道细菌产生的SCFA作为信号分子, “重新编程”免疫细胞到一个更耐受的状态。然而,这个过程也可以被操纵,如肿瘤。 细胞使用SCFAs重新编程免疫细胞以限制炎症并促进肿瘤生长。是否 致病细菌以类似的方式使用SCFA来提高毒力还不清楚。 SCFA是革兰氏阳性病原体链球菌代谢的主要终产物 化脓这种细菌可以在许多粘膜和软组织部位引起疾病, 无症状(阴道)、自限性(咽)、坏死性(皮肤)。免疫系统对 这些组织中的每一个都是不同的,某些组织(例如咽)的感染可导致自身免疫性疾病。 后遗症(风湿热)。这种疾病和免疫力多样性的基础尚不清楚, 确立了习然而,S.化脓性链球菌产生SCFA表明, 操纵疾病耐受性可能起重要作用。 作为一种乳酸菌,S.化脓菌通过几种途径减少丙酮酸 替代途径:通过乳酸脱氢酶和通过混合酸发酵的两个平行分支来乳酸, 其活性受氧调节,以产生额外的SCFA。根据生长条件和 substrates,S.化脓菌将产生不同的SCFA混合物。由于不同类型的免疫细胞在 它们对特定的SCFAs有反应,这表明生长基质和条件的差异 会改变S。化脓菌SCFA组合物改变免疫细胞的类型 这可能导致疾病进展、严重程度和免疫力的组织特异性差异。 为了验证这一假设,我们构建了突变体,无论是单独的,还是在每一个成对的组合,在 丙酮酸还原的三种途径。这些限制了SCFA的生产,使其对定义的集合不敏感, 生长基质的变化。在皮下疾病小鼠模型中的初步分析支持 中心假设,因为一些突变体是完全毒性的,其他突变体显示不同程度的减毒, 有趣是,有些病毒增殖到与野生型相当的水平,但产生明显较少的组织病变。这 后一种行为是操纵疾病耐受性反应的标志。为了更严格地测试 由于SCFAs对毒力的贡献,该提案将这些突变体的分析扩展到其他组织部位, 测试它们对免疫力的影响,它们对调节免疫细胞功能的调节,并将原理分类 所用的生长基质和S.不同组织中的化脓菌。
英文摘要
ABSTRACT Microbial-derived Short Chain Fatty Acids (SCFAs) have emerged as important mediators of “Disease Tolerance,” a process that seeks to limit the collateral damage to host tissues that can accompany immune responses. Best understood in the gut, SCFAs produced by commensal bacteria act as signaling molecules to “reprogram” immune cells to a more toleragenic state. However, this process can also be manipulated, as tumor cells use SCFAs to reprogram immune cells to limit inflammation and promote tumor growth. Whether pathogenic bacteria use SCFAs in a similar fashion to promote virulence is not well-understood. SCFAs are the principle end-products of the metabolism of the Gram-positive pathogen Streptococcus pyogenes. This bacterium can cause diseases at numerous mucosal and soft-tissue sites that range from asymptomatic (vagina), to self-limiting (pharynx) to necrotic (cutaneous). The immune response against the organism differs at each of these tissues and infection at certain tissues (e.g. pharynx) can result in autoimmune sequelae (rheumatic fever). The basis for this diversity of disease and immunity has not been clearly established. However, the ability of S. pyogenes to produce SCFAs suggests that reprogramming resulting in manipulation of disease tolerance may play a significant role. As a lactic acid bacterium, the fermentative metabolism of S. pyogenes reduces pyruvate via several alternative pathways: to lactate via lactate dehydrogenase and by two parallel arms of mixed acid fermentation, whose activities are modulated by oxygen, to produce additional SCFAs. Depending on growth conditions and substrates, S. pyogenes, will produce distinct mixtures of SCFAs. Since different types of immune cells vary in the specific SCFAs they respond to, this suggests that the differences in growth substrates and conditions encountered at diverse tissues will alter S. pyogenes SCFA composition to alter the types of immune cells modulated, which may contribute to tissue-specific differences in disease progression, severity and immunity. To test this hypothesis, we have constructed mutants, both singly and in every pair-wise combination, in the three pathways for pyruvate reduction. These constrain SCFA production to defined ensembles insensitive to changes in growth substrates. Preliminary analysis in a murine model of subcutaneous disease supports the central hypothesis, as some mutants are fully virulent, others show varying degrees of attenuation and most interestingly, some multiply to levels equivalent to wild-type, but produce markedly less tissue pathology. This latter behavior is a hallmark of the manipulation of a disease tolerance response. To more rigorously test the contribution of SCFAs to virulence, this proposal will expand analysis of these mutants to other tissue sites, will test their influence on immunity, their modulation of regulatory immune cell function and will catalog the principle growth substrates utilized and SCFA products produced by S. pyogenes at different tissues.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Therapeutic Approach to Invasive Group A Streptococcal Disease
  • 批准号:
    10452033
  • 项目类别:
  • 资助金额:
    $23.63万
  • 财政年份:
    2022
  • 负责人:
    Michael G. Caparon
  • 依托单位:
Novel Therapeutic Approach to Invasive Group A Streptococcal Disease
  • 批准号:
    10546470
  • 项目类别:
  • 资助金额:
    $19.56万
  • 财政年份:
    2022
  • 负责人:
    Michael G. Caparon
  • 依托单位:
Characterization of assembly factors for type IV secretion systems
  • 批准号:
    10435561
  • 项目类别:
  • 资助金额:
    $25.42万
  • 财政年份:
    2021
  • 负责人:
    Michael G. Caparon
  • 依托单位:
GmPcides: Componds that disarm antibiotic resistance in multiple gram-positive pathogens
  • 批准号:
    10577811
  • 项目类别:
  • 资助金额:
    $39.0万
  • 财政年份:
    2021
  • 负责人:
    Michael G. Caparon
  • 依托单位:
海外基金